Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson’s disease patients-Reference-Cited by-同舟云学术

Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson’s disease patients

Published:2022-11 Issue: Volume:180 Page:101-118
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Wollmer Erik,Klein Sandra

Funder

Federal Ministry of Education and Research Bonn Office

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference98 articles.

1. Impact of gastrointestinal physiology on drug absorption in special populations–An UNGAP review;Stillhart;Eur. J. Pharm. Sci.,2020

2. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions;Nicolas;Biopharm. Drug Dispos.,2017

3. Paediatric pharmacokinetics: key considerations;Batchelor;Br. J. Clin. Pharmacol.,2015

4. Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines;Wollmer;Adv. Drug Deliv. Rev.,2022

5. Age-mediated changes in the gastrointestinal tract;Merchant;Int. J. Pharm.,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys;Xenobiotica;2024-04-17

2. A toolbox for mimicking gastrointestinal conditions in children: Design and evaluation of biorelevant dissolution media for mimicking paediatric gastric- and small intestinal conditions;European Journal of Pharmaceutics and Biopharmaceutics;2023-12

3. Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation;Molecular Pharmaceutics;2023-11-13

4. Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease;Scientific Reports;2023-09-22

5. Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease;2023-03-17